Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $2.0 million as the latest value for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) fell 1.27% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $8.3 million, up 4.11%, while the annual FY2025 figure was $8.3 million, 12.75% up from the prior year.
  • Depreciation & Amortization (CF) hit $2.0 million in Q1 2026 for Kymera Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q3 2025 and bottomed at $687000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.4 million, with a median of $1.5 million recorded in 2024.
  • Year-over-year, Depreciation & Amortization (CF) surged 123.01% in 2024 and then fell 1.27% in 2026.
  • Kymera Therapeutics' Depreciation & Amortization (CF) stood at $818000.0 in 2022, then increased by 8.92% to $891000.0 in 2023, then soared by 123.01% to $2.0 million in 2024, then grew by 2.26% to $2.0 million in 2025, then fell by 0.49% to $2.0 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.0 million, $2.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.